.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,247,316

« Back to Dashboard

Claims for Patent: 7,247,316

Title:Compositions and methods for treating lymphoma
Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.
Inventor(s): Sarris; Andreas H (Houston, TX), Cabanillas; Fernando (Houston, TX), Logan; Patricia M (Vancouver, CA), Burge; Clive T R (Brentwood Bay, CA), Goldie; James H (Vancouver, CA), Webb; Murray S (Delta, CA)
Assignee: Board of Regents, The University of Texas System (Austin, TX) Inex Pharmaceuticals Corporation (CA)
Application Number:10/782,738
Patent Claims: 1. A kit for use in the treatment of a neoplasia in a mammal, said kit comprising: (a) a first vial comprising a solution comprising vincristine sulfate at a concentration of approximately 1 mg/ml, mannitol at a concentration of approximately 100 mg/ml, wherein said solution has a pH in the range of 3.5 to 5.5; (b) a second vial comprising a citrate-buffered solution comprising liposomes comprising sphingomyelin and cholesterol in a ratio of 75/25 (mol % sphingomyelin/mol % cholesterol) to 50/50 (mol % sphingomyelin/mol % cholesterol); (c) a third vial comprising a buffer solution comprising dibasic sodium phosphate heptahydrate at a concentration of approximately 14.2 mg/ml; and (d) instructions for the use of said kit to prepare a liposomal composition useful in the treatment of a neoplasia in a mammal.

2. A kit for use in the treatment of a neoplasia in a mammal, said kit comprising: (a) a first vial comprising a vincristine solution, wherein said vincristine is present at a concentration of 1 mg/ml to 5 mg/ml, wherein said solution has a pH in the range of 3.5 to 5.5; (b) a second vial comprising liposomes in a citrate-buffered solution, wherein said liposomes comprise sphingomyelin and cholesterol in a ratio of 75/25 (mol % sphingomyelin/mol % cholesterol) to 50/50 (mol % sphingomyelin/mol % cholesterol), and wherein the pH of the interior and exterior of said liposomes is acidic; (c) a third vial comprising an alkaline phosphate buffer solution having a pH higher than the pH of the solution of the second vial, such that combining the solutions of the second and third vials results in the pH of the exterior of said liposomes being neutral; and (d) instructions for the use of said kit to prepare liposomal compositions useful in the treatment of a neoplasia in a mammal.

3. A kit for use in the treatment of a neoplasia in a mammal, said kit comprising: (a) a first vial comprising a solution comprising vincristine at a concentration of approximately 1 mg/ml, mannitol at a concentration of approximately 100 mg/ml, wherein said solution has a pH in the range of 3.5 to 5.5; (b) a second vial comprising a citrate-buffered solution comprising liposomes comprising sphingomyelin and cholesterol in a ratio of 75/25 (mol % sphingomyelin/mol % cholesterol) to 50/50 (mol % sphingomyelin/mol % cholesterol); (c) a third vial comprising a buffer solution comprising dibasic sodium phosphate heptahydrate at a concentration of approximately 14.2 mg/ml; and (d) instructions for the use of said kit to prepare a liposomal composition useful in the treatment of a neoplasia in a mammal.

4. The kit of any one of claims 1-3, wherein said neoplasia is a relapsed lymphoma or leukemia.

5. The kit of any one of claims 1-3, wherein the pH of the interior and exterior of said liposome is approximately 4.0.

6. The kit of any one of claims 1-3, wherein said liposome comprises sphingomyelin and cholesterol at a ratio of about 55/45 (mol % sphingomyelin/mol % cholesterol).

7. The kit of any one of claims 1-3, wherein the pH of the alkaline phosphate buffer solution is approximately 9.0.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc